BACKGROUND: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. AIMS: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. METHODS: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. RESULTS: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the "80/80/80 rule," diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8-6.06, P < 0.001). CONCLUSION: SVR was much lower in a real-life patient cohort than in clinical trials (53 % for TVR and 40 % for BOC, compared to 66-75 % in clinical trials).
BACKGROUND: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. AIMS: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. METHODS: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. RESULTS: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOCpatients were more likely to have cirrhosis than TVRpatients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the "80/80/80 rule," diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8-6.06, P < 0.001). CONCLUSION: SVR was much lower in a real-life patient cohort than in clinical trials (53 % for TVR and 40 % for BOC, compared to 66-75 % in clinical trials).
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245
Authors: José Medrano; Pablo Barreiro; Salvador Resino; Paula Tuma; Violeta Rodríguez; Eugenia Vispo; Pablo Labarga; Antonio Madejón; Javier García-Samaniego; Inmaculada Jiménez-Nácher; Luz Martín-Carbonero; Vincent Soriano Journal: Clin Infect Dis Date: 2009-11-01 Impact factor: 9.079
Authors: M Vera-Llonch; M Martin; J Aggarwal; M Donepudi; M Bayliss; T Goss; Z Younossi Journal: Aliment Pharmacol Ther Date: 2013-06-03 Impact factor: 8.171
Authors: Nicholas J Burstow; Zameer Mohamed; Asmaa I Gomaa; Mark W Sonderup; Nicola A Cook; Imam Waked; C Wendy Spearman; Simon D Taylor-Robinson Journal: Int J Gen Med Date: 2017-02-17
Authors: Kian Bichoupan; Neeta Tandon; James F Crismale; Joshua Hartman; David Del Bello; Neal Patel; Sweta Chekuri; Alyson Harty; Michel Ng; Keith M Sigel; Meena B Bansal; Priya Grewal; Charissa Y Chang; Jennifer Leong; Gene Y Im; Lawrence U Liu; Joseph A Odin; Nancy Bach; Scott L Friedman; Thomas D Schiano; Ponni V Perumalswami; Douglas T Dieterich; Andrea D Branch Journal: World J Virol Date: 2017-11-12
Authors: Jona T Stahmeyer; Siegbert Rossol; Florian Bert; Klaus H W Böker; Harald-Robert Bruch; Christoph Eisenbach; Ralph Link; Christine John; Stefan Mauss; Renate Heyne; Eckart Schott; Heike Pfeiffer-Vornkahl; Dietrich Hüppe; Christian Krauth Journal: PLoS One Date: 2016-07-28 Impact factor: 3.240
Authors: Anna Piekarska; Ewa Koślińska-Berkan; Kamila Wójcik; Anna Skubała; Maciej Jabłkowski; Zbigniew Deroń; Aleksandra Berkan-Kawińska Journal: Clin Exp Hepatol Date: 2016-11-28